Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, open-label, randomized controlled trial aimed to
evaluate the efficacy and safety of entecavir and tenofovir versus entecavir alone in the
antiviral treatment of HBV DNA positive B-cell lymphoma patients.
This study plans to enroll about 120 participants in total. Recruitment will last for 2
years.
The study visit will take place on the first day of each cycle of therapy until the end of
the treatment.
Participants who meet the inclusion/exclusion criteria were randomly assigned to receive
entecavir and tenofovir or entecavir alone after signing the informed consent. HBV DNA will
be measured before each cycle of chemotherapy or immunotherapy. When the copy count of HBV
DNA drops below 1*10^3/L, entecavir single agent will be given orally, until one year after
the cycle of therapy.
Treatment response will be evaluated routinely after chemotherapy or immunotherapy.
Within 2 years after the last participant is enrolled, participants' survival information
will collected by telephone and/or clinical visit every 3 months after the last visit (i.e.
date and cause of death, subsequent cancer treatment, etc.), if there is no withdrawal of the
informed consent form.